{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:43:48Z","timestamp":1788983028751,"version":"build-2803163510"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T00:00:00Z","timestamp":1476316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0164830","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T16:05:15Z","timestamp":1476374715000},"page":"e0164830","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["High Potency VEGFRs\/MET\/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1170-3284","authenticated-orcid":true,"given":"Hidenori","family":"Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Gomori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Haruma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Yamamoto-Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomoto","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Sakuragi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yonekura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,10,13]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cllc.2013.05.002","article-title":"Determinants of survival in advanced non\u2014small-cell lung cancer in the era of targeted therapies","volume":"14","author":"J Bauml","year":"2013","journal-title":"Clin Lung Cancer"},{"issue":"20","key":"ref2","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"RE Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JTO.0000000000000051","article-title":"Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13","volume":"9","author":"N Katakami","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"19","key":"ref4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"F Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"9768","key":"ref5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"K Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"15","key":"ref6","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1073\/pnas.93.15.7644","article-title":"Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro","volume":"93","author":"M Grano","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/labinvest.2012.108","article-title":"VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology","volume":"92","author":"RM Taylor","year":"2012","journal-title":"Lab Invest"},{"issue":"2\u20133","key":"ref8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3727\/096504009789954627","article-title":"VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL","volume":"18","author":"H Guan","year":"2009","journal-title":"Oncol Res"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0090-4295(02)01954-4","article-title":"High expression of the Met receptor in prostate cancer metastasis to bone","volume":"60","author":"BS Knudsen","year":"2002","journal-title":"Urology"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s13577-014-0101-3","article-title":"Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis","volume":"28","author":"S Mukai","year":"2015","journal-title":"Hum Cell"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0090-4295(99)00167-3","article-title":"Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer","volume":"54","author":"JL Duque","year":"1999","journal-title":"Urology"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"N Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"ref13","article-title":"Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer","author":"A Varkaris","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","volume":"31","author":"DC Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/med.21258","article-title":"FMS Kinase Inhibitors: Current Status and Future Prospects","volume":"33","author":"MI El-Gamal","year":"2013","journal-title":"Med Res Rev"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1535-7163.MCT-13-0459","article-title":"The novel VEGF receptor\/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile","volume":"12","author":"H Fujita","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"ref17","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/jm0204183","article-title":"Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase","volume":"46","author":"L Sun","year":"2003","journal-title":"J Med Chem"},{"issue":"1","key":"ref18","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer","volume":"9","author":"E Corey","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref19","first-page":"143","article-title":"Modern Bone Histomorphometry","author":"Nango SK Nobuhito","year":"2014"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-62703-989-5_11","article-title":"Preparation of thin frozen sections from nonfixed and undecalcified hard tissues using Kawamot's film method (2012)","volume":"1130","author":"T Kawamoto","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1177\/1087057109345527","article-title":"Optimizing a kinase assay for IKKbeta on an HTS station","volume":"14","author":"N Doti","year":"2009","journal-title":"J Biomol Screen"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nri2062","article-title":"Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems","volume":"7","author":"H Takayanagi","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","article-title":"A multigenic program mediating breast cancer metastasis to bone","volume":"3","author":"Y Kang","year":"2003","journal-title":"Cancer cell"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1172\/JCI22320","article-title":"Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors","volume":"115","author":"AJ Minn","year":"2005","journal-title":"The Journal of clinical investigation"},{"key":"ref25","article-title":"Bone Cancer Primary Bone Cancers and Bone Metastases","author":"D Heymann","year":"2015"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1359\/jbmr.060706","article-title":"Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration","volume":"21","author":"BT Feeley","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1046\/j.1365-2567.2001.01186.x","article-title":"The role of hepatocyte growth factor and its receptor c-met in interactions between lymphocytes and stromal cells in secondary human lymphoid organs","volume":"102","author":"G Skibinski","year":"2001","journal-title":"Immunology"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/ATVBAHA.112.300782","article-title":"Analysis of stromal cell secretomes reveals a critical role for stromal cell-derived hepatocyte growth factor and fibronectin in angiogenesis","volume":"33","author":"AC Newman","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bone.2005.12.006","article-title":"Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB\/c-MC","volume":"39","author":"K Ono","year":"2006","journal-title":"Bone"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbrc.2006.09.076","article-title":"Hepatocyte growth factor can substitute for M-CSF to support osteoclastogenesis","volume":"350","author":"IE Adamopoulos","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/bbrc.1995.1974","article-title":"The effect of hepatocyte growth factor on the behaviour of osteoclasts","volume":"212","author":"K Fuller","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/1535-7163.MCT-11-0277","article-title":"Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown","volume":"11","author":"S Previdi","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-5793(00)01520-9","article-title":"Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts","volume":"473","author":"M Nakagawa","year":"2000","journal-title":"FEBS Lett"},{"issue":"7","key":"ref34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.matbio.2008.06.005","article-title":"VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin","volume":"27","author":"Q Yang","year":"2008","journal-title":"Matrix Biol"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbrc.2005.07.145","article-title":"Vascular endothelial growth factor receptors in osteoclast differentiation and function","volume":"335","author":"SE Aldridge","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"ref36","first-page":"337","article-title":"Canonical and non-canonical pathways of osteoclast formation","volume":"24","author":"HJ Knowles","year":"2009","journal-title":"Histol Histopathol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coph.2015.05.008","article-title":"CSF-1\/CSF-1R targeting agents in clinical development for cancer therapy","volume":"23","author":"CH Ries","year":"2015","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4248\/BR201301003","article-title":"Osteoclasts: New Insights","volume":"1","author":"F Xu","year":"2013","journal-title":"Bone Res"},{"issue":"8","key":"ref39","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.drudis.2014.05.016","article-title":"Targeting IL-34 in chronic inflammation","volume":"19","author":"EL Masteller","year":"2014","journal-title":"Drug Discov Today"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/labinvest.2014.1","article-title":"Colony-stimulating factor 1 potentiates lung cancer bone metastasis","volume":"94","author":"JY Hung","year":"2014","journal-title":"Lab Invest"},{"key":"ref41","article-title":"Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study","author":"N Butowski","year":"2015","journal-title":"Neuro Oncol"},{"issue":"8","key":"ref42","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","article-title":"CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study","volume":"16","author":"PA Cassier","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"ref43","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","article-title":"SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model","volume":"20","author":"LJ Murray","year":"2003","journal-title":"Clin Exp Metastasis"},{"issue":"suppl 7","key":"ref44","article-title":"Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and\/or enzalutamide (E)","volume":"33","author":"MR Smith","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0164830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:14:40Z","timestamp":1588994080000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0164830"}},"subtitle":[],"editor":[{"given":"Sakamuri V.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,13]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0164830","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,13]]}}}